Skip to main content

Clinical Trials Using Gemcitabine

Review the clinical trials studying gemcitabine on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 76-100 of 133

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
Status: Active
Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
A Study Comparing Standard Treatments in People With Non-muscle Invasive Bladder Cancer (NMIBC), COMPARE IT Trial
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Status: Active
Location: 4 locations
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Status: Active
Location: 4 locations
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Status: Active
Location: 3 locations
Bethanechol in Combination with Gemcitabine and Nab-paclitaxel for the Treatment of Borderline Resectable Pancreatic Cancer
Status: Active
Location: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
Status: Active
Location: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
ACR-368 in Combination with Low Dose Gemcitabine for Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Gemcitabine and Carboplatin for the Treatment of Locally Advanced or Metastatic, Progressive Urothelial Carcinoma
Status: Active
Location: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Intravesical Gemcitabine and Docetaxel for the Treatment of Low Grade Intermediate Risk Bladder Cancer
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Pembrolizumab in Combination with Gemcitabine and Cisplatin for Treating Patients with High-Risk Resectable Intrahepatic Cholangiocarcinoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Intravesical Gemcitabine and Docetaxel for the Treatment of Non-muscle Invasive Bladder Cancer
Status: Active
Location: Banner University Medical Center - Tucson, Tucson, Arizona
EUS-RFA PANCARDINAL-1 Trial
Status: Active
Location: The University of Texas Health Science Center, Houston, Houston, Texas
Gemcitabine, Cisplatin, and Pembrolizumab before and after Surgery for the Treatment of Potentially Resectable Biliary Tract Cancer
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Circulating Tumor DNA Monitoring for Treatment Response Prediction and Treatment Reduction after Surgery in Patients with Stage IB, II, and IIIB Non-small Cell Lung Cancer, DNA-PREDICT Trial
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Tertiary and Community Care Models for the Administration of Hepatic Artery Infusion Chemotherapy in Patients with Unresectable or Resectable Colorectal Liver Metastases and Unresectable Intrahepatic Cholangiocarcinoma
Status: Active
Location: University of Kentucky/Markey Cancer Center, Lexington, Kentucky
Chemotherapy and Cemiplimab with or without Alirocumab before Surgery for the Treatment of Lung Cancer in Patients with Stage IB-IIIA Non-small Cell Lung Cancer
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
Comparing two Chemotherapy Regimens (NALIRIFOX and mGAP) in the Treatment of Locally Advanced, Unresectable, and Metastatic Pancreatic Adenocarcinoma
Status: Active
Location: Medical University of South Carolina, Charleston, South Carolina
High Dose Radiation Therapy with Pembrolizumab and Chemotherapy for the Treatment of Patients with PD-L1 Positive Metastatic Triple Negative Breast Cancer
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Y-90 SIRT in Combination with Durvalumab and Gemcitabine and Cisplatin for the Treatment of Locally Advanced, Unresectable, or Metastatic Biliary Tract Cancer
Status: Active
Location: Beth Israel Deaconess Medical Center, Boston, Massachusetts